We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
The current MXCT market cap is 315.69M. The company's latest EPS is USD -0.3664 and P/E is -10.18.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 21.62M | 26.17M | 33.89M | 44.26M | 41.29M |
| Operating Income | -12.42M | -11.06M | -18.19M | -27.36M | -48.3M |
| Net Income | -12.9M | -11.82M | -19.08M | -23.57M | -37.92M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 29.99M | 51.78M | 284.12M | 286.65M | 268.27M |
| Total Liabilities | 16.38M | 18.56M | 21.22M | 32.69M | 36.11M |
| Total Equity | 13.6M | 33.23M | 262.9M | 253.97M | 232.17M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -8.8M | -8.78M | -10.68M | -14.78M | -21.69M |
| Investing | 455k | -16.58M | -195.01M | -24.82M | 54.98M |
| Financing | 12.31M | 28.9M | 234.72M | 2.89M | 2.14M |
| Market Cap | 315.69M |
| Price to Earnings Ratio | -10.18 |
| Price to Sales Ratio | 9.35 |
| Price to Cash Ratio | 8.3 |
| Price to Book Ratio | 1.66 |
| Dividend Yield | - |
| Shares Outstanding | 103.5M |
| Average Volume (1 week) | 16.06k |
| Average Volume (1 Month) | 19.37k |
| 52 Week Change | -24.69% |
| 52 Week High | 420.00 |
| 52 Week Low | 172.50 |
| Spread (Intraday) | 10 (3.23%) |
| Company Name | Maxcyte Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.maxcyte.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
